Ractigen Therapeutics' bladder cancer trial approved

Ractigen Therapeutics has received China NMPA approval for a Phase II clinical trial of its saRNA therapy, RAG-01. This therapy targets non-muscle invasive bladder cancer, marking a significant step in the company's development pipeline. The approval allows Ractigen to further investigate the efficacy and safety of its innovative RNA-based treatment. This advancement underscores the potential of saRNA technology in oncology and Ractigen's progress in bringing novel therapies to patients.